Besides, myriad of clinical trials demonstrated the efficacy of anti-PD1/PD-L1 in many cancer types such as urothelial carcinoma, renal cell carcinoma, small-cell lung cancer [28–30]. Here, CD274 is linked to hereditary clear cell renal cell carcinoma.